Ineligibility for anticoagulation in patients with atrial fibrillation

Ian Del Conde, Jonathan L. Halperin

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Although anticoagulation therapy markedly reduces the risk of stroke in patients with atrial fibrillation, up to 50% of these patients are deemed ineligible for anticoagulation. In this manuscript we provide a framework to assess the net clinical benefit of anticoagulation in patients with atrial fibrillation with an increased risk of bleeding. We also review recent data related to the novel oral anticoagulants targeting thrombin or factor Xa, and discuss how the introduction of these agents raises the distinction between eligibility for vitamin K antagonist therapy specifically, and eligibility for anticoagulation in general.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalAmerican Journal of Medicine
Issue number2
StatePublished - Feb 2013


  • Anticoagulation
  • Atrial fibrillation
  • Bleeding
  • Eligibility
  • Stroke


Dive into the research topics of 'Ineligibility for anticoagulation in patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this